Tissue Collection for Drug Screening and Bioanalysis

Central Nervous System Tumor Clinical Trial

Official title: Tissue Collection for Drug Screening and Bioanalysis

Status Recruiting

Clinical Trial Summary

The purpose of this study is to improve upon the knowledge currently available about pediatric central nervous system (CNS) tumors by further examining biological samples from pediatric patients with tumors undergoing surgery.

Clinical Trial Description

The goal of this project is to enable the acquisition of tissue available for research with the prospect of enabling the development of new therapeutic avenues for patients diagnosed with cancer in the central nervous system.

During pediatric patients' (with a CNS tumor) routine operative procedure, if extra tissue deemed unnecessary for diagnostic or clinical purposes is available, selected samples will undergo DNA and/or RNA extraction and integrity analysis, whole genome and RNA sequencing, DNA and RNA methylome analyses, proteomic analysis, immunoprofiling, and primary culturing of the tumor cells. These cultures may then be used for drug screenings and to create patient-derived xenografts, or for comparisons between tumor and non-tumor patients. Other biological samples may be collected.

Additionally, saliva samples may be obtained from the parents of pediatric patients with CNS tumors, and biological samples may be collected from pediatric patients without a CNS tumor who are undergoing a neurological procedure. These samples may be used for comparison with samples from patients with CNS tumors. ;

Related Conditions & MeSH terms

• Central Nervous System Neoplasms
• Central Nervous System Tumor
• Nervous System Neoplasms
• Pediatric Central Nervous System Tumor

• NCT number: NCT04852354
• Study type: Observational
• Source: Weill Medical College of Cornell University
• Contact: Jeffrey Greenfield, M.D.
• Phone: 212-746-2363
• Email: jpgreenf@med.cornell.edu
• Status: Recruiting
• Start date: July 22, 2020
• Completion date: July 22, 2029